Literature DB >> 18298481

Increased lipolysis by secretory phospholipase A(2) group V of lipoproteins in diabetic dyslipidaemia.

C Pettersson1, L Fogelstrand, B Rosengren, S Ståhlman, E Hurt-Camejo, B Fagerberg, O Wiklund.   

Abstract

BACKGROUND: Lipolysis of lipoproteins by secretory phospholipase A(2) group V (sPLA(2)-V) promotes inflammation, lipoprotein aggregation and foam cell formation--all considered as atherogenic mechanisms.
OBJECTIVE: In this study, we compared the susceptibility to sPLA(2)-V lipolysis of VLDL and LDL from individuals with type 2 diabetes and the metabolic syndrome (T2D-MetS) and from healthy controls. Design. VLDL and LDL were isolated from 38 T2D-MetS subjects and 38 controls, treated pair-wise. Extent of sPLA(2)-V lipolysis was measured as release of nonesterified free fatty acids (NEFA). In a subset of the subjects, lipoprotein composition was determined as a relationship between lipid and apolipoprotein components.
RESULTS: Mean paired increase in sPLA(2)-V lipolysis after 1 h for T2D-MetS versus control was 2.0 micromol NEFA l(-1) for VLDL (P = 0.004) and 0.75 micromol NEFA l(-1) for LDL (P = 0.001). There were also substantial differences in lipoprotein composition between the groups. T2D-MetS VLDL had higher triglyceride and cholesterol contents than control VLDL. T2D-MetS LDL was smaller and contained more triglycerides and less cholesterol than control LDL. Both VLDL and LDL from T2D-MetS subjects also contained more apolipoprotein CIII per particle.
CONCLUSION: VLDL and LDL from T2D-MetS individuals were more susceptible to sPLA(2)-V lipolysis than those from control individuals. This may result in elevated levels of NEFA and lysophosphatidylcholine, both in circulation and in LDL, possibly contributing to the elevated inflammatory state and increased risk of cardiovascular diseases seen in these individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18298481     DOI: 10.1111/j.1365-2796.2008.01932.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  7 in total

1.  A new era of secreted phospholipase A₂.

Authors:  Makoto Murakami; Hiroyasu Sato; Yoshimi Miki; Kei Yamamoto; Yoshitaka Taketomi
Journal:  J Lipid Res       Date:  2015-03-24       Impact factor: 5.922

2.  Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes.

Authors:  M Ståhlman; H T Pham; M Adiels; T W Mitchell; S J Blanksby; B Fagerberg; K Ekroos; J Borén
Journal:  Diabetologia       Date:  2012-01-18       Impact factor: 10.122

3.  The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity.

Authors:  Hiroyasu Sato; Yoshitaka Taketomi; Ayako Ushida; Yuki Isogai; Takumi Kojima; Tetsuya Hirabayashi; Yoshimi Miki; Kei Yamamoto; Yasumasa Nishito; Tetsuyuki Kobayashi; Kazutaka Ikeda; Ryo Taguchi; Shuntaro Hara; Satoshi Ida; Yuji Miyamoto; Masayuki Watanabe; Hideo Baba; Keishi Miyata; Yuichi Oike; Michael H Gelb; Makoto Murakami
Journal:  Cell Metab       Date:  2014-06-05       Impact factor: 27.287

Review 4.  Secreted phospholipase A2, lipoprotein hydrolysis, and atherosclerosis: integration with lipidomics.

Authors:  Kei Yamamoto; Yuki Isogai; Hiroyasu Sato; Yoshitaka Taketomi; Makoto Murakami
Journal:  Anal Bioanal Chem       Date:  2011-03-29       Impact factor: 4.142

5.  Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes.

Authors:  Cecilia Morgantini; Andrea Natali; Beatrice Boldrini; Satoshi Imaizumi; Mohamad Navab; Alan M Fogelman; Ele Ferrannini; Srinivasa T Reddy
Journal:  Diabetes       Date:  2011-08-18       Impact factor: 9.461

Review 6.  Metabolic regulation by secreted phospholipase A2.

Authors:  Hiroyasu Sato; Yoshitaka Taketomi; Makoto Murakami
Journal:  Inflamm Regen       Date:  2016-05-21

7.  New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase.

Authors:  Fatmah A S Alasmary; Fatima S Alnahdi; Abir Ben Bacha; Amr M El-Araby; Nadine Moubayed; Ahmed M Alafeefy; Moustafa E El-Araby
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.